BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
BioBiz Buzz
11. A technological breakthrough in the diagnosis of skin cancer
AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solutions hold the key to helping clinicians with timely diagnosis.
In this episode of BioBiz Buzz, your host Shani Alexander sits down with Christoffer Ekström, CEO of AI Medical Technology, a Swedish-based company which has developed the Dermalyser, a diagnostic decision support system to help healthcare professionals classify skin cancer, such as malignant melanoma, using image analysis combined with the company’s algorithm. All that is needed is a smartphone with the Dermalyser app, a compatible dermatoscope, and a clinical environment with trained healthcare staff.
Clinical validation studies have demonstrated the high diagnostic accuracy of the device with an AUC of 0.96 when both invasive and in-situ melanomas are included, and an even higher AUC of 0.988 when considering invasive melanomas only. For the combined group (invasive + in-situ), Dermalyser achieved a sensitivity of 95.2% and specificity of 84.5%. For invasive melanomas only, sensitivity reached 100% and specificity 92.6%.
The Dermalyser is CE-marked under EU Medical Device Regulation (MDR) and can be used on patients with Fitzpatrick skin types I–IV. AI Medical Technology is working on bringing Dermalyser to clinics across Europe and has an eye on the US market.
Ekström explains that the company’s innovation is more than a technological breakthrough; it represents a fundamental shift in how skin cancer is diagnosed. For patients, it means faster diagnosis, fewer unnecessary surgeries, and potentially life-saving decisions made sooner.
This episode provides insights into a solution that offers hope and will bring peace of mind to the millions of people with a suspected skin lesion.
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)